---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164542"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:05:36.001062+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics shareholders approve 1-for-30 reverse stock split; elect two directors

## Summary
- Reverse stock split at 1-for-30 ratio approved by 40,212,819 votes for, 717,495 against.
- Common stock to begin trading on post-split basis on June 12, 2023 under new CUSIP 31773D200.
- Susan Graf and Chris Shumway elected as Class II directors through 2026; Graf 26,097,717 votes for, Shumway 24,013,503.
- Annual meeting had 40,934,688 shares present (~85.02% of outstanding).

## SEC filing metadata
- accession: 0001193125-23-164542
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/d620811d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164542
- JSON: https://secwatch.observer/filing/0001193125-23-164542.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164542.txt

## Key facts
- Governance Changes
  Finch Therapeutics Group, Inc.: Reverse stock split of common stock at a ratio of 1-for-30 (effective 2023-06-09).
  - Change: charter amendment
  - Effective: 2023-06-09
  source text: On June 9, 2023, Finch Therapeutics Group, Inc. (the “Company”) filed a Certificate of Amendment (the “Charter Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-30.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm
- Shareholder Votes
  Finch Therapeutics Group, Inc. shareholders approved Election of two nominees as Class II directors: Susan Graf and Chris Shumway at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: To elect two nominees as Class II directors: Susan Graf and Chris Shumway, each to hold office until the Annual Meeting of Stockholders in 2026. Nominee Votes For Votes Withheld Broker Non-Votes Susan Graf 26,097,717 4,226,794 10,610,177 Chris Shumway 24,013,503 6,311,008 10,610,177
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm
- Shareholder Votes
  Finch Therapeutics Group, Inc. shareholders approved To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. at the 2023-06-08 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: To approve the Charter Amendment to effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio of 1-for-30. Votes For Votes Against Abstentions Broker Non-Votes 40,212,819 717,495 4,374 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.